The Open Collections site will be undergoing maintenance 8-11am PST on Tuesday Dec. 3rd. No service interruption is expected, but some features may be temporarily impacted.

Open Collections

UBC Faculty Research and Publications

Competing risks of mortality by PAM50 intrinsic subtype of British Columbia tamoxifen-treated cohort of post-menopausal breast cancer patients Chapman, Judith-Anne W.; Liu, Shuzhen; Leung, Samuel; Nielsen, Torsten

Abstract

Background: PAM50 intrinsic subtypes have been shown to impact breast cancer prognosis. Methods: A British Columbia cohort of 718 post-menopausal women treated with tamoxifen, without chemotherapy, had tumours intrinsic-subtyped (Luminal A;Luminal B;Basal;HER2) and centrally-reviewed by immunohistochemical (IHC) for estrogen and progesterone receptor (ER and PgR). We tested whether intrinsic subtype and other patient and tumour characteristics were associated with type of death. Results: At median 11.7 years follow-up, 429 of 718 (60%) women died: 30% of deaths were breast cancer-specific (BrCa); 30%, other type (OT). In 425 women <70 years, 32% died of BrCa and 19% of OT. In 293 >70, 27% died of BrCa and 45% of OT. Intrinsic subtype was associated with BrCa (p=0.001); and older age, with OT (p<0.001). Additionally, step-wise cause-specific models indicated larger tumour size (p<0.001), more positive lymph nodes (p<0.001), and less PgR stain (p=0.03) were associated with worse BrCa survival; more positive lymph nodes (p=0.002) and lymphovascular invasion (p=0.02) were associated with worse OT. Adjusted BrCa and OT survival is provided by factor at 5-, 10-, and 15-years. Conclusions: Intrinsic subtype was associated with BrCa death while age was associated with OT, the majority of deaths in women >70 being from OT.

Item Metadata

Title
Competing risks of mortality by PAM50 intrinsic subtype of British Columbia tamoxifen-treated cohort of post-menopausal breast cancer patients
Creator
Chapman, Judith-Anne W.; Liu, Shuzhen; Leung, Samuel; Nielsen, Torsten
Contributor
Genetic Pathology Evaluation Centre
Publisher
Elsevier
Date Issued
2017-07
Description
Background: PAM50 intrinsic subtypes have been shown to impact breast cancer prognosis. Methods: A British Columbia cohort of 718 post-menopausal women treated with tamoxifen, without chemotherapy, had tumours intrinsic-subtyped (Luminal A;Luminal B;Basal;HER2) and centrally-reviewed by immunohistochemical (IHC) for estrogen and progesterone receptor (ER and PgR). We tested whether intrinsic subtype and other patient and tumour characteristics were associated with type of death. Results: At median 11.7 years follow-up, 429 of 718 (60%) women died: 30% of deaths were breast cancer-specific (BrCa); 30%, other type (OT). In 425 women <70 years, 32% died of BrCa and 19% of OT. In 293 >70, 27% died of BrCa and 45% of OT. Intrinsic subtype was associated with BrCa (p=0.001); and older age, with OT (p<0.001). Additionally, step-wise cause-specific models indicated larger tumour size (p<0.001), more positive lymph nodes (p<0.001), and less PgR stain (p=0.03) were associated with worse BrCa survival; more positive lymph nodes (p=0.002) and lymphovascular invasion (p=0.02) were associated with worse OT. Adjusted BrCa and OT survival is provided by factor at 5-, 10-, and 15-years. Conclusions: Intrinsic subtype was associated with BrCa death while age was associated with OT, the majority of deaths in women >70 being from OT.
Subject
breast cancer; PAM50 intrinsic subtypes; tamoxifen; competing risks; breast cancer specific death; other cause specific death
Genre
Article; Postprint
Type
Text
Language
eng
Date Available
2022-01-06
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0406153
URI
http://hdl.handle.net/2429/80535
Affiliation
Medicine, Faculty of; Non UBC; Pathology and Laboratory Medicine, Department of
Citation
Chapman JW, Liu S, Leung S, Nielsen TO. Competing Risks of Mortality by PAM50 Intrinsic Subtype of British Columbia Tamoxifen-Treated Cohort of Postmenopausal Patients With Breast Cancer. Clin Breast Cancer. 2017 Jul;17(4):e215-e224
Publisher DOI
10.1016/j.clbc.2017.01.002
Peer Review Status
Reviewed
Scholarly Level
Faculty; Other
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International